Navigation Links
Shareholder Class Action Filed Against Elan Corporation, plc by the Law Firm of Barroway Topaz Kessler Meltzer & Check, LLP
Date:12/11/2008

RADNOR, Pa., Dec. 11 /PRNewswire/ --The following statement was issued today by the law firm of Barroway Topaz Kessler Meltzer & Check, LLP:

Notice is hereby given that a class action lawsuit was filed in the United States District Court for the Southern District of New York on behalf of purchasers of the securities of Elan Corporation, plc (NYSE: ELN) ("Elan" or the "Company") between May 21, 2007 and October 21, 2008, inclusive (the "Class Period").

If you wish to discuss this action or have any questions concerning this notice or your rights or interests with respect to these matters, please contact Barroway Topaz Kessler Meltzer & Check, LLP (Darren J. Check, Esq. or David M. Promisloff, Esq.) toll free at 1-888-299-7706 or 1-610-667-7706, or via e-mail at info@btkmc.com.

The Complaint charges Elan and certain of its officers and directors with violations of the Securities Exchange Act of 1934. Elan is a neuroscience-based biotechnology company. The Complaint alleges that during the Class Period the Company made materially false and misleading statements about bapineuzumab, a drug Elan was developing in association with Wyeth for the treatment of Alzheimer's disease. Specifically, Defendants failed to disclose unfavorable results from a Phase II clinical study of bapineuzumab that Elan and Wyeth conducted. When those results were disclosed on July 29, 2008, the price of Elan's shares plunged from $33.75 to $19.63 on extremely high volume. On October 22, 2008, it was reported that some European regulators had asked that trials of bapineuzumab be delayed following the mixed results of the mid-stage U.S. trials. On this news, the price of Elan's shares fell from $9.06 per share to $7.82 per share.

Plaintiff seeks to recover damages on behalf of class members and is represented by the law firm of Barroway Topaz Kessler Meltzer & Check which prosecutes class actions in both state and federal courts throughout the country. Barroway Topaz Kessler Meltzer & Check is a driving force behind corporate governance reform, and has recovered billions of dollars on behalf of institutional and individual investors from the United States and around the world.

For more information about Barroway Topaz Kessler Meltzer & Check or to sign up to participate in this action online, please visit www.btkmc.com.

If you are a member of the class described above, you may, not later than December 15, 2008, move the Court to serve as lead plaintiff of the class, if you so choose. A lead plaintiff is a representative party that acts on behalf of other class members in directing the litigation. In order to be appointed lead plaintiff, the Court must determine that the class member's claim is typical of the claims of other class members, and that the class member will adequately represent the class. Your ability to share in any recovery is not, however, affected by the decision whether or not to serve as a lead plaintiff. Any member of the purported class may move the court to serve as lead plaintiff through counsel of their choice, or may choose to do nothing and remain an absent class member.

    CONTACT:      Barroway Topaz Kessler Meltzer & Check, LLP
                  Darren J. Check, Esq.
                  David M. Promisloff, Esq.
                  280 King of Prussia Road
                  Radnor, PA 19087
                  1-888-299-7706 (toll free) or 1-610-667-7706
                  Or by e-mail at info@btkmc.com


'/>"/>
SOURCE Barroway Topaz Kessler Meltzer & Check, LLP
Copyright©2008 PR Newswire.
All rights reserved

Related biology technology :

1. Microbix Uses Core Business Cashflow To Fund Late-Stage Pipeline To Build Shareholder Value In 2009
2. Favrille and MyMedicalRecords.com, Inc. Obtain Shareholder Approval to Move Forward With Merger
3. Intellect Neurosciences, Inc. Issues Letter to Shareholders From Its Chairman and CEO
4. Trinity Biotech Investor Group Initiates Campaign of ADR Conversion to Force a Special Meeting of Shareholders
5. Trinity Biotech Management Refuses to Honor Call for a Special Meeting of Shareholders
6. Shire Successfully Settles Former TKT Shareholder Appraisal Rights Litigation
7. Human Pheromone Sciences, Inc. - Shareholder Update
8. Angiotech Announces Webcast and Call-in Numbers for Annual and Special General Meeting of Shareholders
9. ProtoKinetix Partners with OTC Financial Network to Increase Shareholder Base
10. Insmed to Seek Shareholder Approval for Reverse Split
11. China-Biotics, Inc. Announces Results of 2008 Annual General Meeting of Shareholders
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:2/27/2017)... Feb. 27, 2017 /PRNewswire/ - InMed Pharmaceuticals, Inc. ("InMed") (CSE: ... on Friday, February 24, 2017 a total of 10,672,750 common ... $0.13 per common share. Proceeds from the exercise of these ... InMed,s Treasury.   ... "We are grateful for this expression of confidence by ...
(Date:2/27/2017)... NEW YORK , February 27, 2017 ... up by Stock-Callers.com for evaluation today, and they are: ... ARWR), Pacific Biosciences of California Inc. (NASDAQ: PACB), and ... to an article on ETF Trends, market observers are ... Congress and administration could enact reforms to free cash ...
(Date:2/27/2017)... , Feb. 27, 2017 Fluxion Biosciences announced ... has been appointed as a Certified Service ... IsoFlux system will be used in Genetracer Biotech,s novel ... lung and colon cancer, with plans to move to ... is utilizing Fluxion,s IsoFlux System to isolate, recover, and ...
(Date:2/27/2017)... ... 27, 2017 , ... The Catalyst Midwest premix manufacturing facility has ... premix services and private label organic services. , The first organic product is Organic ... operating officer of Dynamite Marketing, which owns the facility. , Catalyst already has received ...
Breaking Biology Technology:
(Date:2/7/2017)... Minn. , Feb. 7, 2017   MedNet ... supports the entire spectrum of clinical research, is pleased ... iMedNet , its innovative, highly flexible and award ... iMedNet customers. iMedNet is a proven ... provides Electronic Data Capture (EDC), but also delivers an ...
(Date:2/3/2017)... , Feb. 3, 2017 A new independent ... Strategy Partners, LLP (IdSP) . Designed to fill a ... complex identity market, founding partners Mark Crego ... combined years just in identity expertise that span federal ... non-profit leadership. The Crego-Kephart combined expertise has a common ...
(Date:1/31/2017)... , Jan. 31, 2017  Spero Therapeutics, LLC, ... for the treatment of bacterial infections, today announced ... antibacterial candidates from Pro Bono Bio Ltd (PBB) ... of multi-drug resistant forms of Gram-negative bacteria.   The ... Infectives Ltd, a PBB group company. ...
Breaking Biology News(10 mins):